

Reduced mtDNA Copy Number in the Prefrontal Cortex of C9ORF72 patients

Maria Isabel Alvarez-Mora

Hospital Clinic de Barcelona

Petar Podlesniy

CIBERNED: Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas

Teresa Riazuelo

Hospital Clinic de Barcelona

Laura Molina-Porcel

Hospital Clinic IDIBAPS Neurological Tissue Biobank: Biobanc de l'Hospital Clinic IDIBAPS

Ellen Gelpi

Medical University of Vienna: Medizinische Universitat Wien

Laia Rodriguez-Revenge (✉ lbodi@clinic.cat)

Hospital Clinic de Barcelona <https://orcid.org/0000-0002-6332-3929>

Research Article

Keywords: mtDNA copy number, C9ALS/FTD, neurodegeneration, C9ORF72, ddPCR

Posted Date: July 16th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-698721/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Molecular Neurobiology on January 3rd, 2022. See the published version at <https://doi.org/10.1007/s12035-021-02673-7>.

Abstract

Hexanucleotide repeat expansion in *C9ORF72* gene is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD). Loss of C9ORF72 protein function and a toxic gain-of-function directly by the RNA or RAN translation have been proposed as triggering pathological mechanisms, along with the accumulation of TDP-43 protein. In addition, mitochondrial defects have been described to be a major driver of disease initiation. Mitochondrial DNA copy number has been proposed as a useful biomarker of mitochondrial dysfunction. The aim of our study was to determine the presence of mtDNA copy number alterations in C9ALS/FTD patients. Therefore, we assessed mtDNA copy number in *postmortem* prefrontal cortex from 18 *C9ORF72* brain donors and 9 controls using digital droplet PCR. A statistically significant decrease of 50% was obtained when comparing *C9ORF72* samples and controls. This decrease was independent of age and gender. The reduction of mtDNA copy number was found to be higher in patient samples presenting abundant TDP-43 protein inclusions. A growing number of studies demonstrated the influence of mtDNA copy number reduction on neurodegeneration. Our results provide new insights into the role of mitochondrial dysfunction in the pathogenesis of C9ALS/FTD.

Introduction

In 2011, abnormal expansion of a GGGGCC (G_4C_2) hexanucleotide repeat in a non-coding region of the *C9ORF72* gene was identified as the most common genetic cause of familial and sporadic forms of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9ALS/FTD) [1, 2].

Although the mechanisms of disease of C9ALS/FTD remain unknown, three pathological mechanisms of *C9ORF72* gene mutation have been described. First, loss of function of the C9ORF72 protein through haploinsufficiency [1-3]. Second, a toxic RNA gain-of-function suggested by the accumulation of sense and antisense RNA transcripts containing the G_4C_2 repeat within nuclear foci [4]. Third, gain of function by repeat-associated non-ATG initiated (RAN) translation of dipeptide-repeat protein (DPR) from the sense and antisense strand [reviewed in 5]. Five potential DPRs, called 'poly(GA)', 'poly(GP)', 'poly(GR)', 'poly(PA)' and 'poly(PR)', can be produced by RAN translation [6]. Although the role of DPR in the development of the disease remains uncertain, aggregation of poly(GR) has recently been observed in the brain of patients and associated with neurodegeneration [7, 8]. Apart from DPRs, *postmortem* examinations of C9ALS/FTD brain tissue exhibit cellular inclusions containing transactive response DNA-binding protein 43 kDa (TDP-43). The topographical distribution of this pathology usually determines the phenotype of the disease, i.e. ALS vs FTLD and correlates with the degree of degenerative changes [reviewed in 9]. Of these features, DPR pathology and nuclear RNA foci are unique and highly specific to C9ALS/FTD. In addition to these three molecular mechanisms, many more downstream cellular pathways have been described to be affected in C9ALS/FTD, including nucleo-cytoplasmic transport, RNA processing, function of nucleolus, formation of membrane-less organelles, translation and ubiquitin proteasome system alterations, and DNA damage repair pathways impairment [reviewed in 5, 10]. Despite all efforts, nowadays it is still unclear which molecular events initiate the disease.

Mitochondrial dysfunction is known to be a hallmark of a broad spectrum of diseases, including neurodegenerative disorders, and variation in the mitochondrial DNA (mtDNA) copy number is used as a biomarker of mitochondrial dysfunction. In fact, it is known that mtDNA levels fluctuate in response to the physiological environment surrounding the cell [11], and they have been an attractive, blood-based, non-invasive biomarker for various diseases such as Parkinson's disease and Alzheimer disease [12, 13]. There are several studies supporting a role for mitochondrial dysfunction in the pathogenesis of C9ALS/FTD. It has been shown that poly(GR) in *C9ORF72* neurons compromise mitochondrial function and cause DNA damage in part by increasing oxidative stress [14, 15]. Importantly, these *in vitro* studies revealed that when reducing the levels of poly(GR) or the induced oxidative stress, disease phenotypes were partially suppressed or reversed [14, 15]. Overall, these studies pointed out that mitochondrial defects are a major driver of disease initiation in C9ALS/FTD. In an attempt to provide more insights into the role of mitochondrial dysfunction in C9ALS/FTD, we assessed the mtDNA copy number in human *postmortem* samples of the prefrontal cortex of *C9ORF72* patients in order to decipher its role in the pathogenesis of the disease.

Materials And Methods

Subjects

Deep frozen *postmortem* prefrontal cortex was obtained from 18 C9ALS/FTD brain donors (8 males and 10 females) and 9 controls (5 males and 4 females) with no clinical evidence or neuropathological finding of ALS/FTD. All donors were of Caucasian origin. The disease duration, defined as the time between symptoms onset and death, in the C9ALS/FTD group ranged from 1 to 21 years. Table 1 summarizes clinical, molecular and neuropathological findings of subjects recruited in the study.

No significant difference was observed in gender composition between both groups ($p=0.6$). However, significant differences were detected in terms of C_4C_2 repeat length and age. While all C9ALS/FTD samples exhibited a G_4C_2 repeat expansion greater than 145 repeats, control samples had normal G_4C_2 repeat size ($\leq 23 G_4C_2$). The mean age \pm standard deviation (SD) in years was 79 ± 11 for C9ALS/FTD patients (range 55-88) and 67 ± 9 for controls (range 58-90) ($p=0.004$). Therefore, age was taken into account as a co-variable for statistical correction.

The study was approved by the Ethics Committee of the Hospital Clinic of Barcelona. Brain samples were obtained from the Hospital Clinic-IDIBAPS Brain Bank under approved protocols of the Ethical Committee (Hospital Clinic Barcelona, Spain).

Brain sample preparation

Total mitochondrial and genomic DNA was extracted for each sample using a method that preserves the *in vivo* ratio between them as previously described [16]. Briefly, the frozen brain tissue was rapidly homogenized in 1ml of 100ST-DNA, RNA and protein solubilization buffer (#DCQ100ST, DireCtQuant, Spain) per 10mg of brain tissue using Dounce homogenizer with 25 μ m clearance. The samples were

incubated at 90°C for 3min and centrifuged at 10.000 rcf for 10min. The clear supernatant was transferred to a fresh tube and used to measure the absolute mtDNA copy number and nuclear genomes by digital droplet PCR (ddPCR).

Neuropathological examination

Immunohistochemistry was performed on formalin-fixed and paraffin-embedded tissue blocks applying Anti-C9RANT (Novus Biologicals, Centennial, CO, USA; dilution 1:1,000) and Anti-phosphorylated TDP-43 antibodies (Cosmo Bio, Tokyo, Japan; dilution 1:20,000). The DAKO EnVision© detection kit (Dako, Glostrup, Denmark) was used for visualization of antibody reactions. The frequency of TDP-43 aggregates was scored following a semiquantitative analysis in the frontal cortex. A four-point grading scale (0.5= isolated; 1= sparse; 2= moderate and 3= abundant) was used to evaluate the severity of TDP-43 immunoreactivity. No attempt was made to score cytoplasmic and neuritic lesions separately, but most cases with a high TDP-43 score had dystrophic neurites in addition to neuronal cytoplasmic inclusions.

mtDNA copy number assessment by digital droplet PCR

Digital droplet PCR (ddPCR) technology was chosen to measure the absolute number of mtDNA copies per diploid genome as previously described [16]. Briefly, mtDNA copy number was measured using QX200 Droplet Digital PCR System following manufacture's recommendations (Bio-Rad Laboratories, Inc.) Specific primers were used to amplify a 92 bp fragment from the human mitochondrial sequence and TBP-1 and TEFM genes were used as reference genes.

The presence or absence of amplification per droplet was evaluated using a QX200 Droplet Reader and analyzed using the QuantaSoft Analysis Pro (Bio-Rad Laboratories) software. An assumption that a diploid genome contains 2 copies of each single copy gene *TBP-1/TEFM* was used. mtDNA copy number was calculated by dividing the number of mtDNA copies detected by number of diploid genomes (measured by *TBP-1/TEFM*).

Statistical analysis

Results were expressed as mean \pm standard error means (SEM). For comparisons of the means, the statistical significance of the differences was examined using general linear model univariate analysis, the parametric independent *t*-Test or the non-parametric Mann–Whitney U and Kruskal-Wallis tests. Correlations were studied using Pearson correlations. All statistical analyses were performed by the SPSS program, version 25 (SPSS, Inc. Chicago, IL, USA). Significance was accepted for p-value <0.05.

Results

We studied the mtDNA copy number in *postmortem* prefrontal cortex obtained from 18 C9ALS/FTD patients compared to 9 control samples. The amount of mtDNA copy number was analyzed by ddPCR and results are shown as the mtDNA copy number per diploid genome (Figure 1). A statistically

significant decrease was observed when comparing C9ALS/FTD samples (3,923 mtDNA copies/diploid genome \pm 566) with controls (7,364 mtDNA copies/diploid genome \pm 909) ($p=0.003$) (Figure 1). Moreover, taking into account the age of individuals as a co-variable the reduction in the mtDNA copy number in *C9ORF72* prefrontal cortex was statistically significant (linear model univariate analysis C9ALS/FTD vs. controls with age as a covariate, marginal means for C9ALS/FTD: 3,818 \pm 648 and controls: 7,574 \pm 968; $p=0.006$). We further performed Pearson correlation analysis to determine the association between mtDNA copy number and age in C9ALS/FTD patients and controls. There was no correlation between mtDNA copy number and age ($R^2=0.05$, $p=0.26$).

Having shown a significant 50% decrease in the mtDNA copy number in prefrontal cortex of C9ALS/FTD patients, we investigated whether this decline was correlated with the abundance of DPR inclusions or TDP-43 aggregates. Neuropathological examination evidenced DPR inclusions and TDP-43 aggregates in all frontal cortex of C9ALS/FTD patients. While no differences could be determined regarding the abundance of DPR inclusions since all samples exhibited high abundance of these inclusions across all cortical layers, the semiquantitative analysis of TDP-43 aggregates showed differences in its frequency (Figure 2). The correlation analysis with mtDNA copy number evidenced that, C9ALS/FTD patients with isolated or sparse TDP-43 inclusions ($n=6$) showed a reduction of 35% in the mtDNA copy number compared to controls (Figure 3 and Table 2). This reduction was more evident in the group of C9ALS/FTD patients with moderate/severe inclusions ($n=12$), in which a mtDNA copy number reduction of 63% was obtained when comparing to the control group and of 42% when comparing to C9ALS/FTD patients with isolated or sparse TDP-43 inclusions (Figure 3 and Table 2). Statistical analysis identified only significant differences when comparing mtDNA copy number between controls and C9ALS/FTD patients with moderate/abundant TDP-43 inclusions ($p=0.009$) (Figure 3 and Table 2). These results suggest that C9ALS/FTD patients with isolated/sparse TDP-43 inclusions in prefrontal cortex brain region might represent an intermediate state in terms of neuronal cell degeneration or death.

Finally, we further analyzed whether there was a relationship between mtDNA copy number and clinical manifestation of *C9ORF72* expansion patients. Patients were divided into three groups based on clinical manifestations: C9ALS, C9FTD and C9ALS/FTD. Although no statistically significant differences were obtained, those patients diagnosed as C9ALS/FTD showed the lowest mtDNA copy number value (Figure 4).

Discussion

Mitochondria are subcellular organelles which have multiple important roles, including ATP production, Ca^{2+} homeostasis, and reactive oxygen species (ROS) production [reviewed in 17]. Each mitochondrion contains multiple copies of mtDNA that encode the transfer RNAs and mitochondria specific ribosomal RNAs necessary for the mitochondrial protein synthesis, as well as the essential proteins required for oxidative phosphorylation. Mitochondrial DNA integrity is necessary for mitochondrial maturation during differentiation of neural stem cells, and in fact, several quality control systems counteract processes that lead to mitochondrial dysfunction [18]. Loss of mtDNA integrity by altered mtDNA copy number and

increased mutations is implicated in cellular dysfunction with aging and disease [19]. A growing number of studies demonstrated the influence of mtDNA copy number reduction on neurodegeneration [eg. 20-22].

Although the exact pathogenetic mechanism of C9ALS/FTD is still elusive, several evidences suggest that damaged mitochondrial likely play a fundamental role [23-25]. The relevance of DPR pathology in causing C9ALS/FTD has also been widely discussed and it is currently believed that its production is a key molecular event downstream of *C9ORF72* repeat expansion [24, 26-28]. In *C9ORF72* cellular and animal models it has been reported that DPR proteins, specially poly(GR), have a toxic effect in an accumulative and age-dependent manner; compromising several cellular pathways such as mitochondrial function and causing DNA damage by increasing oxidative stress [7, 8, 14, 15, 29]. It has been suggested that DPR protein aggregation precedes and instigates TDP-43 pathology [30; reviewed in 31]. Recently it has been shown that toxic poly(GR) proteins mediate sequestration of full-length TDP-43 in an RNA-independent manner, promoting TDP-43 proteinopathy [32].

This study investigated the changes in mtDNA copy number in prefrontal cortex of patients with C9ALS/FTD. Additionally, the study evaluated the relationship between mtDNA copy number and the clinical phenotype. For these purposes, we used a ddPCR technique since it is a highly sensitive and specific method for absolute quantification of mtDNA copy number and the ratio of mtDNA per cell. Results showed a statistically significant mtDNA copy number reduction of 50% in C9ALS/FTD patients compared to controls ($p=0.006$). All our samples showed marked DPR pathology; making it difficult to establish differences, whereas the frequency of TDP-43 aggregate was different among the C9ALS/FTD samples analyzed. Even the sample size was relatively small, we found a positive correlation between the abundance of TDP-43 inclusions and the mtDNA copy number decrease, meaning that those patients presenting with moderate or abundant TDP-43 inclusions showed an even more pronounced mtDNA copy number reduction than those with isolated or sparse inclusions (Figure 3). The relationship between mitochondrial dysfunction and TDP-43 proteinopathy has been previously documented. Alterations in mitochondrial dynamics, trafficking and mitophagy have been reported in association with TDP-43 pathology [reviewed in 33]. To our knowledge, this is the first study that shows a reduction of mtDNA copy number in human C9ALS/FTD *postmortem* brain samples that correlates with the abundance of TDP-43 inclusions. Our results might reflect a late-stage of mitochondrial impairment and suggest that TDP-43 inclusion formation contributes in an accumulative manner reducing the mtDNA content and finally, further compromising survival or disease progression.

The *C9ORF72* expansion is associated with clinical heterogeneity, with affected patients displaying symptoms of either ALS or FTD, or mixed features of both. Although several factors have been analyzed, such as the repeat expansion length and the distribution and amount of TDP-43 and DPR protein aggregation, results are inconclusive and the molecular basis for this clinical variation is still unknown [reviewed in 31]. Reports on clinical and neuropathological correlation with DPR protein pathology have been conflicting. While some authors found no relationship between specific DPR species and clinicopathologic subtypes of *C9ORF72*-related disease [34], others describe either a correlation with

DPR distribution [35] or neurodegeneration [8]. In our experience the distribution of TDP-43, and not DPR pathology, determines the clinical phenotype (unpublished data). In this line, although our results need validation in a larger series of cases, they showed a positive tendency correlation between the mtDNA copy number and the clinical phenotype. mtDNA copy number in the prefrontal cortex of *C9ORF72* patients was lower in cases with ALS/FTD than in cases with ALS and FTD (Figure 4). Thus, although interpreted with caution, these results suggest that an impaired mitochondrial function could be more pronounced in *C9ORF72* patients with ALS/FTD phenotype.

Conclusions

Together, our results are in agreement with similar reductions in mtDNA copy number reported in a number of other age-related neurological disorders where mitochondrial dysfunction is also a pathogenic hallmark. We have observed a significant reduction of mtDNA copy number in C9ALS/FTD patients, particularly associated with the amount of TDP43 pathology. This novel finding might help to unravel the role of mitochondrial dysfunction in the pathogenesis of C9ALS/FTD. Overall, these data suggest that the preservation of mitochondrial genome copy number may play a crucial role in replacing damaged mitochondrial complexes to maintain ATP levels and preserve cell viability under stress. As in other neurodegenerative disorders, C9ALS/FTD should be considered as a complex progressive disease with multifactorial pathophysiology, in which different biological, environmental and genetic factors interplay in neuronal degeneration. The increased understanding of C9ALS/FTD pathogenesis casts hope for finally making available a true neuroprotective therapeutic strategy that can be applied at early stages of the disease.

Declarations

Acknowledgments

We are grateful to the Neurological Tissue Bank of the Biobanc- Hospital Clinic-IDIBAPS for sample and data procurement. We thank patients and relatives for generous brain donation for research. We thank Núria Serra for providing technical assistance in ddPCR experiments. This work was supported by the Instituto de Salud Carlos III (PI17/01067), co-financed by Fondo Europeo de Desarrollo Regional (FEDER) “una manera de hacer Europa”, AGAUR from the Autonomous Catalan Government (2017SGR1134) and Ministerio de Ciencia, Innovación y Universidades (SAF2017-89791-R). The CIBER de Enfermedades Raras y Neurodegenerativas are initiatives of the Instituto de Salud Carlos III. Preliminary data was presented in the 53rd European Society of Human Genetics (ESHG) Conference as an interactive e-Poster, June 6-9, 2020 (Eur J Hum Genet 28, 141–797 (2020). <https://doi.org/10.1038/s41431-020-00739-z>).

Funding: This work was supported by the Instituto de Salud Carlos III (PI17/01067), co-financed by Fondo Europeo de Desarrollo Regional (FEDER) “una manera de hacer Europa”.

Conflicts of interest: the authors declare no conflict of interest.

Ethics approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the Hospital Clinic of Barcelona. Brain samples were obtained from the Hospital Clinic-IDIBAPS Brain Bank under approved protocols of the Ethical Committee (Hospital Clinic Barcelona, Spain).

Availability of data and material (data transparency): The datasets of the current study are available upon request with no restriction.

Code Availability: Not applicable.

Consent for Publication: Not applicable.

Consent to Participate: Not applicable.

Author contribution:

Maria Isabel Alvarez-Mora: formulation and evolution of overarching research goals. Preparation and presentation of the published work

Petar Podlesniy: development and design of methodology

Teresa Riazuelo and Nuria Serra: conducting research and investigation process

Laura Molina: provision of study materials and preparation of the published work

Ellen Gelpi: preparation and presentation of the published work and critical review.

Laia Rodriguez-Revengea: formulation and evolution of overarching research goals. Preparation and presentation of the published work

References

1. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72: 245-256.
2. Renton AE, Majounie E, Waite A, et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72: 257-268.
3. Gijselinck I, Van Langenhove T, van der Zee J, et al. (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. *Lancet Neurol* 11: 54-65.

4. Lee YB, Chen HJ, Peres JN, et al. (2013) Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic, *Cell Rep* 5:1178–1186.
5. Rodriguez CM, Todd PK. (2019) New pathologic mechanisms in nucleotide repeat expansion disorders. *Neurobiol Dis* 130: 104515
6. Green KM, Linsalata AE, Todd PK (2016) RAN translation-What makes it run? *Brain Res* 1647: 30-42.
7. Saberi, S. Stauffer JE, Jiang J, et al. (2018) Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. *Acta Neuropathol* 135: 459–474.
8. Sakae, N. Bieniek KF, Zhang YJ, et al. (2018) Poly-GR dipeptide repeat polymers correlate with neurodegeneration and clinicopathological subtypes in C9ORF72-related brain disease. *Acta Neuropathol Commun* 6: 63.
9. Mackenzie IR, Frick P, Neumann M (2014) The neuropathology associated with repeat expansions in the C9ORF72 gene. *Acta Neuropathol* 127: 347-357.
10. Babić Leko M, Župunski V, Kirincich J, et al. (2019) Molecular Mechanisms of Neurodegeneration Related to C9orf72 Hexanucleotide Repeat Expansion. *Behav Neurol* 2019: 2909168.
11. Lee SR, Han J (2017) Mitochondrial Nucleoid: Shield and Switch of the Mitochondrial Genome. *Oxid Med Cell Longev* 2017:8060949.
12. Podlesniy P, Figueiro-Silva J, Llado A, et al. (2013) Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. *Ann Neurol* 74: 655-668.
13. Podlesniy P, Vilas D, Taylor P, et al. (2016) Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease. *Neurobiol Dis* 94: 10-17.
14. Choi SY, Lopez-Gonzalez R, Krishnan G, et al. (2019) C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. *Nat Neurosci* 22: 851-862.
15. Lopez-Gonzalez R, Lu Y, Gendron TF, et al. (2016) Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. *Neuron* 92: 383-391.
16. Alvarez-Mora MI, Podlesniy P, Gelpi E, et al. (2019) Fragile X-associated tremor/ataxia syndrome: Regional decrease of mitochondrial DNA copy number relates to clinical manifestations. *Genes Brain Behav* 18: e12565.
17. Cowan K, Anichtchik O, Luo S (2019) Mitochondrial integrity in neurodegeneration. *CNS Neurosci Ther* 25: 825-836.

18. Wang W, Osenbroch P, Skinnies R, et al. (2010) Mitochondrial DNA integrity is essential for mitochondrial maturation during differentiation of neural stem cells. *Stem Cells* 28: 2195-2204.
19. Szklarczyk R, Nooteboom M, Osiewacz HD (2014) Control of mitochondrial integrity in ageing and disease. *Philos Trans R Soc Lond B Biol Sci* 369: 20130439.
20. Wei W, Keogh MJ, Wilson I, et al. (2017) Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. *Acta Neuropathol Commun* 5: 13.
21. Petersen MH, Budtz-Jørgensen E, Sørensen SA, et al. (2014) Reduction in mitochondrial DNA copy number in peripheral leukocytes after onset of Huntington's disease. *Mitochondrion* 17: 14-
22. Rice AC, Keeney PM, Algarzae NK, et al. (2014) Mitochondrial DNA copy numbers in pyramidal neurons are decreased and mitochondrial biogenesis transcriptome signaling is disrupted in Alzheimer's disease hippocampi. *J Alzheimers Dis* 40: 319-330.
23. Khalil B, Liévens JC (2017) Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway? *Neural Regen Res* 12: 1052-1061.
24. Dafinca R, Scaber J, Ababneh N, et al. (2016) C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. *Stem Cells* 34: 2063-2078.
25. Paillusson S, Stoica R, Gomez-Suaga P, et al. (2016) There's Something Wrong with my MAM; the ER-Mitochondria Axis and Neurodegenerative Diseases. *Trends Neurosci* 39: 146-157.
26. Davidson YS, Barker H, Robinson AC, et al. (2014) Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. *Acta Neuropathol Commun* 2: 70.
27. Mackenzie IR, Arzberger T, Kremmer E, et al. (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. *Acta Neuropathol* 126: 859-879.
28. Zu T, Liu Y, Banez-Coronel M, et al. (2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. *Proc Natl Acad Sci* 110: E4968–E4977.
29. Lee YB, Baskaran P, Gomez-Deza J, et al. (2017) C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity. *Hum Mol Genet* 26: 4765-4777.
30. Chew J, Gendron TF, Prudencio M, et al. (2015) Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. *Science* 348: 1151-1154.

31. Gendron TF, Petrucelli L (2018) Disease Mechanisms of C9ORF72 Repeat Expansions. Cold Spring Harb Perspect Med 8: a024224.
32. Cook CN, Wu Y, Odeh HM, et al. (2020) C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci Transl Med 12: eabb3774.
33. Briston T, Hicks AR (2018) Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention. Biochem Soc Trans 46: 829-842.
34. Mackenzie IR, Frick P, Grässer FA, et al. (2015) Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol 130: 845-861.
35. Schludi MH, May S, Grasser FA, et al. (2015) Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol 130: 537– 555.

Tables

Table 1. Clinical, molecular and neuropathological findings of patients and controls included in the study. TDP-43 inclusions were semiquantitatively assessed in the prefrontal cortex as: 0= absent, 0.5= isolated, 1= sparse; 2= moderate and 3= abundant.

| ID sample | Gender | Age at disease onset (years) | Age at death (years) | Diagnostic group | C9orf72 (GGGGCC)n | TDP-43 inclusions in prefrontal cortex |
|-------------------|--------|------------------------------|----------------------|------------------|-------------------|--|
| Control_1 | Male | - | 78 | control | 2,2 | 0 |
| Control_2 | Male | - | 83 | control | 2,7 | 0 |
| Control_3 | Female | - | 81 | control | 2,8 | 0 |
| Control_4 | Male | - | 64 | control | 2,6 | 0 |
| Control_5 | Female | - | 90 | control | 2,2 | 0 |
| Control_6 | Male | - | 58 | control | 2,13 | 0 |
| Control_7 | Female | - | 88 | control | 2,4 | 0 |
| Control_8 | Female | - | 83 | control | 5,10 | 0 |
| Control_9 | Male | - | 86 | control | 2,2 | 0 |
| <i>C9ORF72_1</i> | Male | 51 | 61 | FTD | >145 | 2 |
| <i>C9ORF72_2</i> | Female | 65 | 66 | FTD/ALS | >145 | 2 |
| <i>C9ORF72_3</i> | Female | 68 | 71 | FTD/ALS | >145 | 1 |
| <i>C9ORF72_4</i> | Female | 63 | 69 | FTD/ALS | >145 | 3 |
| <i>C9ORF72_5</i> | Male | 61 | 66 | FTD | >145 | 3 |
| <i>C9ORF72_6</i> | Female | 52 | 55 | FTD | >145 | 3 |
| <i>C9ORF72_7</i> | Male | 87 | 88 | FTD | >145 | 1 |
| <i>C9ORF72_8</i> | Male | 55 | 69 | FTD | >145 | 2 |
| <i>C9ORF72_9</i> | Female | 53 | 57 | ALS | >145 | 0.5 |
| <i>C9ORF72_10</i> | Female | 65 | 75 | FTD | >145 | 0.5 |
| <i>C9ORF72_11</i> | Female | 55 | 58 | FTD/ALS | >145 | 3 |
| <i>C9ORF72_12</i> | Male | 72 | 73 | FTD | >145 | 2 |
| <i>C9ORF72_13</i> | Female | 67 | 69 | FTD | >145 | 0.5 |
| <i>C9ORF72_14</i> | Female | 56 | 57 | FTD/ALS | >145 | 3 |
| <i>C9ORF72_15</i> | Male | 52 | 55 | ALS | >145 | 3 |
| <i>C9ORF72_16</i> | Male | 75 | 80 | FTD | >145 | 1 |
| <i>C9ORF72_17</i> | Male | 65 | 69 | FTD | >145 | 2 |

| | | | | | | |
|------------|--------|----|----|-----|------|---|
| C9ORF72_18 | Female | 35 | 61 | FTD | >145 | 3 |
|------------|--------|----|----|-----|------|---|

FTD: frontotemporal dementia, ALS: amyotrophic lateral sclerosis.

Table 2. MtDNA copy number observed in prefrontal cortex from 9 controls and 18 C9ALS/FTD donors. Statistical analysis was performed by univariate linear model analysis. Data are expressed as marginal means estimated at 71 years of age ± standard error of the mean (SEM).

| | Mean | SEM | p-value vs control |
|---|-------|-------|--------------------|
| Controls (n=9) | 7,883 | 960 | |
| C9ALS/FTD (n=18) | | | |
| With isolated/sparse TDP-43 inclusions (n=6) | 5,105 | 1,035 | 0.082 |
| (n=12) With moderate/abundant TDP-43 inclusions | 2,943 | 841 | 0.009 |

Figures




Figure 1

Comparison of mtDNA copy number in human postmortem prefrontal cortex from controls (n=9) and C9ALS/FTD (n=18) brain samples. Data is represented as mtDNA copies/diploid genome. The mtDNA copy number of C9ORF72 patients was significantly lower than that of the control group ($p=0.003$)





Figure 2

Representative postmortem neuropathological image of two C9ORF72 patients (C9ORF72_16 and C9ORF72_15 in Table 1) showing different frequency of TDP-43 inclusions. (a) Significant wispy threads and abundant small neurons with diffuse granular cytoplasmic TDP43 staining in C9ORF72_16 patient with moderate/abundant TDP-43 inclusions. (b) C9ORF72_15 patient with isolated/sparse TDP-43 inclusions in cortical areas. Isolated neuron with diffuse granular cytoplasmic TDP43 staining. No differences in the frequency of C9RANT inclusions were observed between the C9ORF72_16 patient with abundant (c) and the C9ORF72_15 with sparse (e) TDP-43 pathology. Detail of cytoplasmic C9RANT inclusions in neurons in C9ORF72_16 (d) and C9ORF72_15 (f) patient. Scale Bar A-B: 50um;C-F: 20um

mtDNA copy number/nuclear genome



TDP-43 Inclusion frequency

Figure 3

Relationship of prefrontal cortex mtDNA copy number and frequency of TDP-43 inclusions in C9ALS/FTD brain samples




Figure 4

Effect of C9ORF72 expansion clinical phenotype on mtDNA copy number in ALS patients (n=2), FTD patients (n=11) and ALS/FTD patients (n=5). Data are expressed as mean \pm SEM